Filing Details
- Accession Number:
- 0000899243-17-018014
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-07-06 18:26:35
- Reporting Period:
- 2017-07-05
- Filing Date:
- 2017-07-06
- Accepted Time:
- 2017-07-06 18:26:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1420565 | Aileron Therapeutics Inc | ALRN | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1709976 | Jr. M. Brian Gallagher | C/O S.r. One, Limited 161 Washinton Street, Suite 500 Conshohocken PA 19428 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-07-05 | 1,158,186 | $0.00 | 1,158,186 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2017-07-05 | 273,333 | $15.00 | 1,431,519 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series D Preferred Stock | Disposition | 2017-07-05 | 6,781,770 | $0.00 | 682,476 | $0.00 |
| Common Stock | Series E-2 Preferred Stock | Disposition | 2017-07-05 | 1,471,551 | $0.00 | 148,088 | $0.00 |
| Common Stock | Series E-3 Preferred Stock | Disposition | 2017-07-05 | 1,276,389 | $0.00 | 128,448 | $0.00 |
| Common Stock | Series F Preferred Stock | Disposition | 2017-07-05 | 1,979,188 | $0.00 | 199,173 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- The Series D, Series E-2, Series E-3 and Series F Preferred converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- S.R. One, Limited, an indirect wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of these shares. Dr. Brian M. Gallagher, Jr. is a partner and Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect wholly-owned subsidiary of GlaxoSmithKline plc. Dr. Gallagher disclaims beneficial ownership of all shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purpose of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
Billionaire Hedge Funds
